{"id":963798,"date":"2026-05-17T10:18:01","date_gmt":"2026-05-17T14:18:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/"},"modified":"2026-05-17T10:18:01","modified_gmt":"2026-05-17T14:18:01","slug":"nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/","title":{"rendered":"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer"},"content":{"rendered":"<h2>\nData presented by Johnson &amp; Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">PARIS and CAMBRIDGE, Mass., May  17, 2026  (GLOBE NEWSWIRE) &#8212; \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=336AgiuVOy_-hKlDPYXmoWXopolUmOlItgRDYIoD--i41VEpAtApFjOA70IhLdAQ1aGDCOM-DeJ7lseZirThTQ==\" rel=\"nofollow\" target=\"_blank\"><u>NANOBIOTIX<\/u><\/a> (Euronext: NANO &#8211; NASDAQ: NBTX &#8211; the \u201cCompany\u201d), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson &amp; Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (\u201cNSCLC\u201d), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026).<\/p>\n<p align=\"justify\">\n        <strong>PRESENTATION #116: Radiographic Response in Patients with Stage III Unresectable Non-Small Cell Lung Cancer Treated with an Intratumoral Radioenhancer (JNJ-90301900) <\/strong>\n      <\/p>\n<p align=\"justify\">Jeffrey Bradley,<sup>1<\/sup> Benjamin T. Cooper,<sup>2<\/sup> Sushma Patel,<sup>3<\/sup> David DiBardino,<sup>4<\/sup> Michael Pritchett,<sup>5<\/sup> Kevin C. Ma,<sup>4<\/sup>\u00a0\u00a0 Isaac Laniado,<sup>6<\/sup> Melina E. Marmarelis,<sup>7<\/sup> Matthew Scarlotta,<sup>8<\/sup> Joshua K. Sabari,<sup>9<\/sup> Yi -Wen Ma,<sup>10<\/sup> Tori Stromp,<sup>10<\/sup> Yina Kuang,<sup>10<\/sup> Balaji Laxmanan,<sup>10 <\/sup>Kiran Devisetty,<sup>10<\/sup> Steven Feigenberg<sup>1<\/sup><\/p>\n<p align=\"justify\">\n        <u>Study Conclusions<\/u>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Early results suggest that intratumoral\/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">Initial efficacy responses observed in 7 patients following the full treatment regimen of concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and consolidation with durvalumab are promising:\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Overall response rate (\u201cORR\u201d) = 85.7% (6\/7 patients)<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">Complete response rate (\u201cCRR\u201d) = 57.1% (4\/7 patients)\n<ul type=\"square\">\n<li style=\"margin-bottom:6pt;text-align:justify\">With the current standard of care, concurrent chemoradiation therapy (cCRT) \u00b1\u202fdurvalumab, depth of response remains limited in Stage 3 Inoperable NSCLC with very low rates of complete response (&lt;5%) *\u00a0<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">Disease control rate (\u201cDCR\u201d) = 100.0% (7\/7 patients)<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">Absence of progressive disease and deepening response over time suggests potential for long-term durability<\/li>\n<\/ul>\n<p>\n        <sup>1<\/sup>Radiation Oncology, University of Pennsylvania, Philadelphia, USA; <sup>2<\/sup>Radiation Oncology, NYU Langone Health, New York, USA; <sup>3<\/sup>Radiation Oncology, FirstHealth of the Carolinas, Pinehurst, USA; <sup>4<\/sup>University of Pennsylvania, Philadelphia, USA; <sup>5<\/sup>Interventional Pulmonology, FirstHealth of the Carolinas, Pinehurst, USA; <sup>6<\/sup>Interventional Pulmonology, NYU Langone Health, New York, USA; <sup>7<\/sup>Medical Oncology, University of Pennsylvania, Philadelphia, USA; <sup>8<\/sup>Medical Oncology, FirstHealth of the Carolinas, Pinehurst, USA; <sup>9<\/sup>Medical Oncology, NYU Langone Health, New York, USA; <sup>10<\/sup>Johnson &amp; Johnson, New Brunswick, NJ, USA<\/p>\n<p>* Antonia SJ, et al. N Engl J Med. 2017.<\/p>\n<p align=\"justify\">\n        <strong>About JNJ-1900 (NBTXR3)<\/strong>\n      <\/p>\n<p align=\"justify\">JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas through a successful randomized Phase 2\/3 study in 2018. The product candidate\u2019s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.<\/p>\n<p align=\"justify\">Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. The program is led by NANORAY-312\u2014a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy\u2014the same population being evaluated in the Phase 3 study.<\/p>\n<p align=\"justify\">Given the Company\u2019s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson &amp; Johnson company.<\/p>\n<p>\n        <strong>About NANOBIOTIX<\/strong>\n      <\/p>\n<p align=\"justify\">Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n<p align=\"justify\">Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.<\/p>\n<p align=\"justify\">Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.<\/p>\n<p align=\"justify\">For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter<strong>.<\/strong><\/p>\n<p align=\"justify\">\n        <strong>Disclaimer<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains \u201cforward-looking\u201d statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company\u2019s anticipates its financial resources will be adequate to support operations. Words such as \u201cexpects\u201d, \u201cintends\u201d, \u201ccan\u201d, \u201ccould\u201d, \u201cmay\u201d, \u201cmight\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cshould\u201d and \u201cwill\u201d or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company\u2019 management\u2019s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix\u2019s business and financial performance, which include the risk that assumptions underlying the Company\u2019s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix\u2019s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under \u201cItem 3.D. Risk Factors\u201d, in Nanobiotix\u2019s 2025 universal registration document filed with the AMF on March 31, 2026 under \u201cchapter 1.5 Risk Factors\u201d, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, which are available on the SEC\u2019s website at www.sec.gov and on the AMF&#8217;s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.<\/em>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <em>Nanobiotix<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>Communications Department<\/strong><br \/>\n            <br \/>\n            <em>Brandon Owens<\/em><br \/>\n            <br \/>\n            <em>VP, Communications<\/em><br \/>\n            <br \/>+1 (617) 852-4835<br \/><u>contact@nanobiotix.com<\/u><\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>Investor Relations Department<\/strong><br \/>\n            <br \/>\n            <em>Joanne Choi<\/em><br \/>\n            <br \/>\n            <em>VP, Investor Relations (US)<\/em><br \/>\n            <br \/>+1 (713) 609-3150<br \/>joanne.choi@nanobiotix.com<\/p>\n<p><em>Ricky Bhajun<\/em><br \/><em>Director, Investor Relations (EU)<\/em><br \/>+33 (0) 79 97 29 99<br \/><u>investors@nanobiotix.com<\/u><\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <em>Media Relations<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">\n<p>France \u2013 <strong>HARDY<\/strong><br \/>Caroline Hardy<br \/>+33 06 70 33 49 50<br \/><a href=\"mailto:carolinehardy@outlook.fr\" rel=\"nofollow\" target=\"_blank\">carolinehardy@outlook.fr<\/a><\/p>\n<\/td>\n<td style=\"border-top: solid black 1pt;vertical-align: middle\">\n            <br \/>Global \u2013 <strong>uncapped<\/strong><br \/>Becky Lauer <br \/>+1 (646) 286-0057<br \/><a href=\"mailto:uncappednanobiotix@uncappedcommunications.com\" rel=\"nofollow\" target=\"_blank\">uncappednanobiotix@uncappedcommunications.com<\/a>\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a href=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/bc7eeb3c-06de-4bd2-a5dd-59041bd01ff0\" rel=\"nofollow\" target=\"_blank\">2026-05-17 &#8212; NBTX &#8212; Part 1 Ph2 NBTXR3 In Stage 3 Lung Cancer &#8212; FINAL<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2MwZDNmMTEtZjdkNC00Mzc2LThjMDUtMmM4ZTdkYmVkYmViLTEwMTExNjItMjAyNi0wNS0xNy1lbg==\/tiny\/Nanobiotix-S-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data presented by Johnson &amp; Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0NANOBIOTIX (Euronext: NANO &#8211; NASDAQ: NBTX &#8211; the \u201cCompany\u201d), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson &amp; Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (\u201cNSCLC\u201d), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response in Patients with Stage III Unresectable Non-Small Cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963798","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data presented by Johnson &amp; Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0NANOBIOTIX (Euronext: NANO &#8211; NASDAQ: NBTX &#8211; the \u201cCompany\u201d), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson &amp; Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (\u201cNSCLC\u201d), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response in Patients with Stage III Unresectable Non-Small Cell &hellip; Continue reading &quot;Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-17T14:18:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer\",\"datePublished\":\"2026-05-17T14:18:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/\"},\"wordCount\":1146,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/\",\"name\":\"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=\",\"datePublished\":\"2026-05-17T14:18:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Market Newsdesk","og_description":"Data presented by Johnson &amp; Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0NANOBIOTIX (Euronext: NANO &#8211; NASDAQ: NBTX &#8211; the \u201cCompany\u201d), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson &amp; Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (\u201cNSCLC\u201d), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response in Patients with Stage III Unresectable Non-Small Cell &hellip; Continue reading \"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-17T14:18:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer","datePublished":"2026-05-17T14:18:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/"},"wordCount":1146,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/","name":"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=","datePublished":"2026-05-17T14:18:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTM4OCM3NjA2MzA0IzEwMTExNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963798"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963798\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}